A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor. Highlights Background With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no longer being sold? It’s much more challenging to prove the original disclosure date for a secondhand item, especially in a jurisdiction like China, which has very stringent notarization and legalization1 requirements for introducing evidence into a proceeding. The case below demonstrates an example of how one major Chinese robot company successfully dug up and introduced…
-
-
New Fee Standards Released for Chinese Patent Applications
Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE). Please find our summary below: PCT application fee deduction rules Application fee & extra fees (claims/pages) Substantive examination fee PCT application type Before Jul 26, 20242 After Jul 26, 2024 Before Jul 26, 2024 After Jul 26, 2024 CNIPAas RO CNIPA as ISA or IPEA 100% OFF 100% OFF 100% OFF 100% OFF non-CN as ISA or IPEA EPO as ISA JPO as ISA SPO as ISA 100% OFF…
-
Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the biggest markets in the world. Any shortening of the patent term for this key semaglutide patent in China could cause an immediately shift in the Chinese Ozempic market (not to mention directly impacting Novo Nordisk). Novo Nordisk’s Semaglutide Patent in China On September 5, 2022, the China National Intellectual Property Association (China’s patent administrative office,…
